Dermoid cyst with secretion of CA 19-9 detected by 18F-FDG PET/CT

A case report

Sheng-Che Lin, MD, Ruoh-Fang Yen, MD, PhD, Yen-Kung Chen, MD, PhD

Abstract

Introduction: Carbohydrate antigen 19-9 (CA 19-9) is a tumor glycolipid, frequently elevated in the serum of patients due to malignancies from gastrointestinal organs, in particular the pancreas. This carbohydrate antigen is also expressed in benign diseases.

Patient concerns: A case of a 27-year-old female who has an unknown origin CA 19-9 elevation for 2 years.

Diagnosis: After the left ovarian cystectomy and microscopic examination, the final diagnosis is a dermoid cyst. The dermoid cyst shows increased 18F-fluorodeoxyglucose (18F-FDG) uptake in the 18F-FDG positron emission tomography (PET)/computed tomography (CT) study.

Intervention and outcomes: The laparoscopic oophorocystectomy was performed. It was observed that the patient’s CA 19-9 level returned to normal after the surgery 6 months later. This showed that the dermoid cyst was responsible for the abnormal CA 19-9 level.

Conclusion: In this case, we can learn that the 18F-FDG PET/CT scan has potential use in patients with unknown origin of elevation CA 19-9.

Abbreviations: 18F-FDG = 18F-fluorodeoxyglucose, CA 19-9 = carbohydrate antigen 19-9, MRI = magnetic resonance imaging, PET/CT = positron emission tomography/computed tomography.

Keywords: 18F-FDG PET/CT, dermoid cyst, CA19-9

1. Introduction

A dermoid cyst, also known as mature teratoma, is a common benign tumor of the ovary. It accounts for 10% to 20% of all ovarian neoplasms and is composed of a well-differentiated derivation of three germ cell layers (endoderm, mesoderm, and ectoderm). Dermoid cysts are asymptomatic in most cases and are benign over 98% cases. In our report, a dermoid cyst with secretion of carbohydrate antigen 19-9 (CA 19-9) is detected by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT).

2. Clinical course

A 27-year-old female was referred to our PET center for a whole-body 18F-FDG PET/CT study. She had been noted to have persistently high serum CA 19-9 up to 3498 U/mL for 2 years before this PET study in a health examination. Gastrointestinal system disease had been ruled out by endoscopy, abdominal ultrasound, CT, and magnetic resonance imaging (MRI) with negative results.

PET/CT imaging was performed 60 minutes after intravenous injection of 10 mCi 18F-FDG. The resulting images revealed a well-defined large tumor with fatty component, greasy fluid component, calcification of bony fragment or tooth, and soft tissue component in her left pelvic cavity. Mild 18F-FDG uptake was observed in the areas containing soft tissue component (Fig. 1A). Based on the PET/CT findings, the left ovarian dermoid cyst was diagnosed.

3. Interventions

The laparoscopic oophorocystectomy was performed. A 9.2 × 6.1 × 6.2 cm cystic lesion with smooth external surface was removed. This cyst was intact and found to have presence of hair, yellowish friable material and focal calcification and was confirmed, via microscope, to be a dermoid cyst composed of squamous epithelium, skin appendages, gastrointestinal, and respiratory tract epithelium. By immunohistochemistry, strong CA 19-9 staining was demonstrated in the epithelium (Fig. 1B).
4. Outcomes

It was observed that the patient’s CA 19-9 level returned to normal (11.2 U/mL) 6 months after the operation. Before operation, the CA 19-9 level is 3498.3 U/mL and the CEA level is 0.47 ng/mL. This showed that the dermoid cyst was responsible for the abnormal CA-19-9 level. Informed written consent was obtained from the patient for publication of this case report and accompanying images.

5. Discussion

CA 19-9 is a tumor glycolipid, frequently elevated in the serum of patients due to malignancies from gastrointestinal organs; in particular, the pancreas. CA 19-9 was identified by a murine monoclonal antibody against a colorectal carcinoma epithelial cell. This carbohydrate antigen is also expressed in benign diseases, as well as pancreatic or biliary ductal epithelial cancers. However, elevated serum CA 19-9 has also been observed for some patients with either benign or malignant dermoid cysts. It has also been reported that CA 19-9 staining is prominently noted around the apical cytoplasm of the epithelial lining. This phenomenon has led Arabekoglu et al to suggest that CA 19-9 is secreted into the cystic cavity. Inflammation or rupture of dermoid cyst, or direct serum excretion via epithelial surface into the bloodstream may therefore result in the elevation of serum CA 19-9. As a consequence, CA 19-9 is suited for being a marker for surveying recurrence. Manni Wang report a case shows elevation of CA19-9 (1329.7IU/mL) and FDG PET/CT positive finding. The pathological diagnosis was left ovarian cancer, an immature teratoma grade 1.

The routine serum CA 19-9 level testing has no utility as a screening tool in asymptomatic patients. Even among patients with symptoms suspicious for pancreatic cancer, elevated CA 19-9 is a poor predictor of pancreatic cancer with a predictive value of 0.5% to 0.9%.

We suspect that the increased 18F-FDG uptake at the soft tissue component of the dermoid cyst may be attributed to the glucose utilization as the energy source for the functionally active secreting epithelium. The 18F-FDG PET/CT scan has potential use in patients with unknown origin of elevation CA19-9.

Author contributions

Data curation: ShengChe Lin.
Investigation: ShengChe Lin, Ruoh-Fang Yen.
Methodology: Yen-Kung Chen.
Writing – original draft: ShengChe Lin.
Writing – review & editing: Yen-Kung Chen.

References

[1] Albert MB, Steinberg WM, Henry JP. Elevated serum levels of tumor marker CA19-9 in acute cholangitis. Dig Dis Sci 1988;33:1223–5.
[2] Richter JM, Christensen MR, Rustgi AK, et al. The clinical utility of the CA19-9 radioimmunoassay for the diagnosis of pancreatic cancer presenting as pain or weight loss. A cost-effectiveness analysis. Arch Intern Med 1989;149:2292–7.
[3] Paganuzzi M, Onetto M, Marroni P, et al. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases. Cancer 1988;61:2100–8.
[4] Micke O, Schafer U, Willich N. Persistent elevation of CA 19-9 levels in a patient with an extended retroperitoneal dermoid. Anticancer Res 1999;19:2717–20.

[5] Ito K. Significance of CA 19-9 in mature cystic teratoma. Nippon Sanka Fujinka Gakkai Zasshi 1992;44:524–8.

[6] Rha SE, Byun JY, Jung SE, et al. Atypical CT and MRI manifestations of mature ovarian cystic teratomas. AJR Am J Roentgenol 2004;183:743–50.

[7] Atabekoglu C, Bozaci EA, Tezcan S. Elevated carbohydrate antigen 19-9 in a dermal cyst. Inter J Gynaecol Obstet 2005;91:262–3.

[8] Nagata H, Takahashi K, Yamane Y, et al. Abnormally high values of CA 125 and CA 19-9 in women with benign tumors. Gynecol Obstet Invest 1989;28:165–8.

[9] Wang M, Jiang S, Zhang Y, et al. The application of 18F-FDG PET/CT in ovarian immature teratomas when pathological examination results contradict clinical observations: a case report. Medicine (Baltimore) 2017;96:e9171.

[10] Ballehaninna UK, Chamberlain RS. Serum CA 19-9 as a biomarker for pancreatic cancer – a comprehensive review. Indian J Surg Oncol 2011;2:88–100. doi: 10.1007/s13193-011-0042-1.